Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report released on Friday morning. The firm issued a sell rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Navidea Biopharmaceuticals stock opened at $0.00 on Friday. The stock has a market cap of $100,084.00, a price-to-earnings ratio of -0.02 and a beta of 1.47. Navidea Biopharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.11.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.